8-K: Femasys Inc. Receives Nasdaq Delisting Notice Over Low Market Value and Financial Non-Compliance

Femasys Inc. has received a notice from The Nasdaq Stock Market LLC indicating non-compliance with continued listing requirements due to its market value of listed securities falling below the $35.0 million minimum, alongside failing alternative financial standards.

Summary

• Femasys Inc. (FEMY) received a written notice from The Nasdaq Stock Market LLC on May 19, 2025, stating non-compliance with continued listing requirements.
• The company's Market Value of Listed Securities (MVLS) has been below the minimum $35.0 million requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2).
• Femasys also does not meet the alternative Nasdaq continued listing standards of at least $2.5 million in stockholders' equity or $500,000 in net income in the most recently completed fiscal year or in two of the three most recently completed fiscal years.
• The notice has no immediate effect on the listing of FEMY common stock, which will continue to trade on Nasdaq under the symbol FEMY.
• Femasys has a 180-calendar-day period, until November 17, 2025, to regain compliance with the Minimum MVLS Requirement.
• Compliance can be regained if the MVLS of the company's common stock closes at $35.0 million or more for a minimum of 10 consecutive business days.
• If compliance is not regained by the deadline, Nasdaq will notify the company that its common stock is subject to delisting, at which point Femasys may appeal the determination to a Nasdaq hearings panel.
• The company intends to actively monitor its MVLS and consider options to regain compliance, but there is no assurance of success.

Sentiment

Score: 2

Explanation: The document conveys a highly negative sentiment as it announces the company's non-compliance with Nasdaq listing requirements, indicating significant financial distress and the risk of delisting. There are no positive counterpoints or mitigating factors mentioned within the filing.

Negatives

• Receipt of a formal notice from Nasdaq regarding non-compliance with continued listing requirements.
• Market Value of Listed Securities (MVLS) has fallen below the $35.0 million minimum for 30 consecutive business days.
• Failure to meet alternative Nasdaq listing standards, including a minimum of $2.5 million in stockholders' equity.
• Failure to meet alternative Nasdaq listing standards, including a minimum of $500,000 in net income in the most recently completed fiscal year or two of the three most recently completed fiscal years.
• Risk of delisting from The Nasdaq Capital Market if compliance is not regained by November 17, 2025.
• No assurance provided that the company will regain compliance or maintain compliance with any other Nasdaq listing requirements.

Risks

• The primary risk is the potential delisting of Femasys Inc.'s common stock from The Nasdaq Capital Market if it fails to regain compliance with the Minimum MVLS Requirement of $35.0 million by November 17, 2025.
• There is a risk that the company may not be able to maintain compliance with other Nasdaq continued listing requirements even if the MVLS issue is resolved.
• Delisting could significantly reduce the liquidity and marketability of the company's common stock, potentially impacting shareholder value.

Future Outlook

Femasys Inc. plans to actively monitor the Market Value of Listed Securities of its common stock and will explore available options to regain compliance with Nasdaq's minimum MVLS requirement by November 17, 2025. However, the company explicitly states there is no assurance that it will successfully regain or maintain compliance with this or any other Nasdaq listing requirements.

Management Comments

• "The Company intends to actively monitor the MVLS of its Common Stock between now and November 17, 2025, and will consider its available options to regain compliance with the Minimum MVLS Requirement."
• "There can be no assurance that the Company will regain compliance with the Minimum MVLS Requirement or maintain compliance with any of the other Nasdaq continued listing requirements."

Industry Context

This filing is specific to Femasys Inc.'s compliance with Nasdaq listing rules, rather than broader industry trends. However, it highlights a common challenge for smaller public companies, particularly those in the biotechnology or medical device sectors, which may face difficulties maintaining market capitalization and profitability thresholds required for continued exchange listing, especially during periods of market volatility or slower product development cycles.

Comparison to Industry Standards

• Femasys Inc.'s failure to meet Nasdaq's minimum listing standards for Market Value of Listed Securities ($35.0 million), stockholders' equity ($2.5 million), and net income ($500,000) indicates a significant underperformance relative to the baseline requirements for publicly traded companies on a major U.S. exchange.
• These thresholds represent standard minimums for Nasdaq Capital Market listing, which numerous companies successfully maintain. Femasys's current status falls short of these general industry benchmarks for public market viability, suggesting a weaker financial position compared to its peers that meet these criteria.

Stakeholder Impact

• Shareholders: Face significant potential negative impact due to the risk of delisting, which could lead to reduced liquidity, lower stock price, and increased difficulty in trading shares. The lack of assurance regarding regaining compliance adds to investment uncertainty.

Next Steps

• Actively monitor the Market Value of Listed Securities (MVLS) of its common stock.
• Consider available options to regain compliance with the Minimum MVLS Requirement.
• Regain compliance by November 17, 2025, by having the MVLS close at $35.0 million or more for a minimum of 10 consecutive business days.
• Potentially appeal a delisting determination to a Nasdaq hearings panel if compliance is not regained by the deadline.

Key Dates

Recommendation

Keywords

Femasys Inc., FEMY, Nasdaq, Delisting Notice, Market Value of Listed Securities, MVLS, Listing Compliance, Stockholders' Equity, Net Income, SEC Filing, 8-K